0001346302-21-000014.txt : 20210201
0001346302-21-000014.hdr.sgml : 20210201
20210201162053
ACCESSION NUMBER: 0001346302-21-000014
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210129
FILED AS OF DATE: 20210201
DATE AS OF CHANGE: 20210201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shannon John Patrick Jr
CENTRAL INDEX KEY: 0001553595
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38536
FILM NUMBER: 21576942
MAIL ADDRESS:
STREET 1: DURATA THERAPEUTICS, INC.
STREET 2: 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR
CITY: MORRISTOWN
STATE: NJ
ZIP: 07960
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: XERIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001346302
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203352427
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 180 NORTH LASALLE STREET
STREET 2: SUITE 1600
CITY: CHICAGO
STATE: IL
ZIP: 60601
BUSINESS PHONE: 844-445-5704
MAIL ADDRESS:
STREET 1: 180 NORTH LASALLE STREET
STREET 2: SUITE 1600
CITY: CHICAGO
STATE: IL
ZIP: 60601
4
1
wf-form4_161221443653827.xml
FORM 4
X0306
4
2021-01-29
0
0001346302
XERIS PHARMACEUTICALS INC
XERS
0001553595
Shannon John Patrick Jr
C/O XERIS PHARMACEUTICALS, INC.
180 N. LASALLE STREET, SUITE 1600
CHICAGO
IL
60601
0
1
0
0
See Remarks
Common Stock
2021-01-29
4
A
0
150000
0
A
271224
D
These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These restricted stock units vest in three substantially equal annual installments beginning on January 29, 2022.
President and Chief Operating Officer
/s/ Beth Hecht, as Attorney-in-Fact
2021-02-01